Drug class profile · refreshed daily from federal data

Lincosamide (Antibiotic)

1 molecule in this class, $64.3M combined CY2024 Part D spend across 4.2M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Lincosamide (Antibiotic) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $64.3Mcombined across class
Total Rx claims: 4.2M3.0M unique beneficiaries
Generic mfrs (active): 26across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Clindamycin

Brand: CLEOCIN PHOSPHATE · 4.2M Part D claims (CY24) · 3.0M beneficiaries · First FDA approval: 1970-05-22

26 generic mfrs 138 plans require PA Active FDA shortage

Low NADAC$0.107

→

Avg plan cost$1.91

Part D spend $64.3M 18× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.